ImmunityBio (NASDAQ:IBRX) Shares Down 6.9% – Time to Sell?

ImmunityBio, Inc. (NASDAQ:IBRX)’s share price dropped 6.9% on Wednesday . The stock traded as low as $7.01 and last traded at $7.14. Approximately 19,330,790 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 38,808,844 shares. The stock had previously closed at $7.67.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Neutral Sentiment: Multiple law firms are issuing investor alerts and soliciting lead-plaintiff candidates for a class period of January 19, 2026 to March 24, 2026 with a common May 26, 2026 deadline — procedural notices that increase visibility of the litigation but are routine in securities suits. ROSEN investor notice
• Negative Sentiment: The FDA sent a warning letter flagging misleading efficacy claims about Anktiva attributed to the company’s executive chairman/CSMO, prompting coverage that the company faces regulatory scrutiny — a substantive catalyst that likely drove prior sharp share declines and raises reputational and regulatory risk. GlobeNewswire: FDA warning & Hagens Berman
• Negative Sentiment: Multiple law firms (Hagens Berman, Kessler Topaz, Robbins Geller, Pomerantz, Faruqi, Rosen, Schall, etc.) have filed or announced suits and investor reminder notices asserting securities-fraud claims related to alleged misstatements about Anktiva — increasing potential litigation exposure and uncertain financial/legal outcomes. Kessler Topaz filing

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. BTIG Research assumed coverage on ImmunityBio in a research report on Thursday, March 12th. They set a “buy” rating and a $13.00 price target on the stock. HC Wainwright boosted their price objective on ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Jefferies Financial Group upped their target price on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Piper Sandler reiterated an “overweight” rating and set a $12.00 target price (up from $7.00) on shares of ImmunityBio in a research report on Wednesday, March 4th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Stock Performance

The stock has a market capitalization of $7.51 billion, a PE ratio of -19.21 and a beta of 0.13. The stock’s 50 day moving average is $7.73 and its two-hundred day moving average is $4.35.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million during the quarter. Equities research analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Insider Activity at ImmunityBio

In related news, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barry J. Simon sold 75,000 shares of the firm’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total value of $900,750.00. Following the completion of the transaction, the director owned 2,850,821 shares in the company, valued at $34,238,360.21. The trade was a 2.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 501,967 shares of company stock valued at $4,466,412 over the last quarter. 69.48% of the stock is owned by company insiders.

Hedge Funds Weigh In On ImmunityBio

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in ImmunityBio by 18.5% during the 4th quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock valued at $64,899,000 after acquiring an additional 5,122,052 shares in the last quarter. State Street Corp boosted its holdings in shares of ImmunityBio by 45.4% during the 4th quarter. State Street Corp now owns 16,455,703 shares of the company’s stock worth $32,582,000 after purchasing an additional 5,139,890 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of ImmunityBio by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock worth $15,684,000 after purchasing an additional 1,030,113 shares during the last quarter. Armistice Capital LLC purchased a new stake in shares of ImmunityBio in the second quarter valued at approximately $20,497,000. Finally, Heights Capital Management Inc. purchased a new stake in shares of ImmunityBio in the third quarter valued at approximately $16,152,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.